Women’s Dissatisfaction With Body Image Can Affect Smoking

Publication
Article
OncologyONCOLOGY Vol 12 No 6
Volume 12
Issue 6

Women smokers who overestimate their body size may be more likely to continue smoking, said researchers at The Miriam Hospital in Providence. Results of a study led by Teresa K. King, PhD, of the hospital’s Center for Behavioral and

Women smokers who overestimate their body size may be more likely to continue smoking, said researchers at The Miriam Hospital in Providence. Results of a study led by Teresa K. King, PhD, of the hospital’s Center for Behavioral and Preventive Medicine, were presented at a recent meeting of the Society of Behavioral Medicine.

Participants in the study were 141 women smokers who had been recruited as part of a smoking cessation trial at the hospital. The women completed an evaluation to ascertain their perceptions of their body size and whether they were satisfied with those perceptions.

At the end of the treatment, only 4 (18.2%) of the 22 women who overestimated their body size relative to their peers had managed to stay off cigarettes, compared with 12 (50%) of the 24 women who underestimated their body size, and 28 (29.5%) of the 95 women who neither overestimated nor underestimated their body size.

The results suggest that body image may play an important role in the smoking behavior of women. Women who overestimate their body size and/or evaluate their body negatively may be more likely to continue smoking--perhaps to prevent weight gain.

Recent Videos
The mechanism of CTO1681 may allow it to reduce the production of a broad range of proinflammatory cytokines in DLBCL.
Younger and fitter patients with relapsed/refractory multiple myeloma were more likely to receive bispecific antibodies in community oncology settings.
Mechanistic treatment benefits were observed in the phase 2 STEM trial for patients with multiple myeloma.
Data from a retrospective cohort study showed that one-fifth of patients with multiple myeloma received bispecific antibodies in rural community settings.
Being able to treat patients with cevostamab who have multiple myeloma after 1 to 3 prior lines of therapy vs 4 lines may allow for better outcomes.
Using the monitoring of symptoms and quality of life platform may provide a quick and efficient system for patients to submit outcome data.
2 experts are featured in this series.
With many treatments emerging in the EGFR-mutated lung cancer landscape, sequencing therapy has emerged as a key consideration for these patients.
Related Content